Asuragen
2005
FOUNDED
PRIVATE
STATUS
101-200
EMPLOYEES
Series C
LATEST DEAL TYPE
$7.5M
LATEST DEAL AMOUNT
5
INVESTORS
Description
Developer of molecular diagnostic products intended to change the way patients are treated in genetics and oncology. The company's molecular diagnostic products have high quality, sensitivity and simplicity to deliver true precision medicine, enabling medical professionals to understand critical clinical situations.
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Diagnostic Equipment
Primary Office
- 2150 Woodward Street
- Suite 100
- Austin, TX 78744
- United States
+1 (512) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Asuragen’s full profile, request a free trial.
Asuragen Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC (Series C) | 20-Mar-2013 | $7.5M | 000.00 | 00000 | Completed | Generating Revenue |
| 5. Grant | 30-Mar-2012 | 00.00 | 000.00 | Completed | Generating Revenue | |
| 4. Later Stage VC (Series C) | 11-Aug-2011 | 000 | 000.00 | 000.00 | Completed | Generating Revenue |
| 3. Grant | 08-Oct-2008 | 00.00 | 000.00 | Completed | Startup | |
| 2. Early Stage VC (Series B) | 10-Dec-2007 | $18.5M | $67.4M | 000.00 | Completed | Startup |
| 1. Early Stage VC (Series A) | 01-Jun-2006 | $48.9M | $48.9M | 000.00 | Completed | Startup |
Asuragen Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 00.000 | |
| Series B | 00,000,000 | 00.000000 | 00.0 | 00.0 | 00 | 00.0 | 00.000 | |
| Series A | 48,895,000 | $0.001000 | $1 | $1 | 1x | $1 | 55.48% |
Asuragen Competitors (18)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| ELITech Group | Private Equity-Backed | Puteaux, France | 000 | 000.00 | 000000000000 | |
| 00000 00000000 | Private Equity-Backed | Aliso Viejo, CA | 000 | 00000 | 000000&0 | 00000 |
| 000000 000000000 | Formerly PE-Backed | Codolet, France | 000 | 000000&0 | ||
| 000000 00000000000 | Venture Capital-Backed | Cambridge, MA | 00 | 00000 | 0000000000 0 | 00000 |
| 000000 00000000 | Venture Capital-Backed | Buffalo, NY | 00.000 | 0000000000 0 | 00.000 |
Asuragen Investments (2)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 00000 000000000000 | 01-Jan-2009 | 00000 00000 00 | 000 | Biotechnology | 0000000 0000000 00.0 |
| Mirna Therapeutics | 04-Apr-2008 | Seed Round | 000 | Biotechnology | 0000000 0000000 00.0 |
Asuragen Exits (2)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 00000 000000000000 | 01-Jan-2009 | 00000 00000 00 | 000 | Completed |
|
| Mirna Therapeutics | 04-Apr-2008 | Seed Round | 000 | Completed |
Asuragen Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| State Of Texas Real Estate Fund | Real Estate | 000 0000 | 000000 0 | |||
| Merck Global Health Innovation Fund | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | ||
| PTV Healthcare Capital | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Southwest Middle Market M&A | Merchant Banking Firm | Minority | 000 0000 | 000000 0 | ||
| Telegraph Hill Partners | Venture Capital | Minority | 000 0000 | 000000 0 |
Asuragen Executive Team (18)
9 Former Executives
You’re viewing 5 of 18 executives. Get the full list »Asuragen Board Members (10)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Christopher Earl Ph.D | Self | Board Member | 000 0000 | |
| David Rubin Ph.D | Merck & Co. | Board Member | 000 0000 | |
| David Sargent | Self | Board Member | 000 0000 | |
| Deval Lashkari Ph.D | Telegraph Hill Partners | Board Member | 000 0000 | |
| J. Matthew Mackowski | Telegraph Hill Partners | Board Member | 000 0000 |
1 Former Board Member
You’re viewing 5 of 10 board members. Get the full list »